monoclonal factor IX replacement therapy
199/11956
Phase 2 small_molecule completed
Quick answer
monoclonal factor IX replacement therapy for Hemophilia B is a Phase 2 program (small_molecule) at Ultragenyx Pharmaceutical with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Ultragenyx Pharmaceutical
- Indication
- Hemophilia B
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed